Panuramine

Panuramine

Panuramine is a pharmacological compound that belongs to the class of antidepressant drugs. It is also known as Wy-26002, a name given by its developer, Wyeth. Panuramine is a serotonin and norepinephrine reuptake inhibitor (SNRI), which means it works by increasing the levels of these neurotransmitters in the brain.

History

Panuramine was first synthesized in the 1970s by the pharmaceutical company Wyeth. Despite promising results in early clinical trials, the development of Panuramine was discontinued for unknown reasons. The compound is not currently available for medical use.

Pharmacology

As a serotonin and norepinephrine reuptake inhibitor (SNRI), Panuramine works by blocking the reuptake of these neurotransmitters into the presynaptic neuron. This increases the amount of these neurotransmitters available in the synaptic cleft, which can enhance neurotransmission and improve symptoms of depression.

Clinical Use

While Panuramine showed promise in early clinical trials, it is not currently approved for use in any country. Therefore, it has no established clinical uses. However, its mechanism of action is similar to that of other SNRIs, which are commonly used to treat depression, anxiety disorders, and certain types of chronic pain.

Side Effects

The potential side effects of Panuramine are not well-studied, due to the discontinuation of its development. However, other SNRIs can cause side effects such as nausea, dry mouth, sweating, dizziness, and sexual side effects. It is possible that Panuramine could cause similar side effects.

See Also

• Serotonin-norepinephrine reuptake inhibitor
• Antidepressant
• Wyeth

This article is a stub related to pharmacology. You can help WikiMD by expanding it!